Inhibitory oligonucleotide having the general formula: (I) are disclosed which can be used in pharmaceutical compositions, whereby in formula (I) C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar, 2-0-methylcytidine, 5-bromocytidine, 5-hydroxycytidine, ribocytidine and cytosine-P-D-arabinofuranoside, G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine, a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base and the guanosine nucleoside sugar, X1 and X3 is any nucleotide sequence with 0 to 12 bases and each nucleotide is independent of any other, X2 is any nucleotide sequence having 0 to 3 nucleotides, N2 and N3 are each independently any nucleotide, N4 and N7 is a pyrimidine or a modified pyrimidine, N5 is a purin or a modified purin, N6 is a modified pyrimidine, A or a modified purin, wherein at least two of the nucleotides N4, N5, N6 or N7 are modified purins or modified pyrimidines.Un olignucleótido inhibitorio que tiene la fórmula general: es divulgado y que se puede usar en composiciones farmacéuticas, con lo cual en la fórmula (I) en donde C es citidina o un derivado de la misma, con lo cual el derivado de citidina se selecciona del grupo que consiste en 5-metilcitidina, un nucleótido tipo citidina que tiene una modificación química que involucra la base de citosina, azúcar de nucleósido de citidina o la base de citosina y el azúcar de nucleósido de citidina, 2-O-metilcitidina, 5-bromocitidina, 5-hidroxicitidina, ribocitidina y citosina-P-D-arabinofuranósido, G es guanosina o un derivado de la misma, con lo cual el derivado de guanosina se seleccio
